BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Biotech catalysts in 2025-12

321 industry Phase 2/3 trial readout(s) and 51 FDA decision event(s). Readouts include completed (ACTUAL) and still-estimated primary completion dates in this month, any status.

← 2025-11 | 2026-01 →

FDA decision events

DateEventStatusCompanyDrugSource
2025-12-02FDA approvalapprovedLOXO ONCOLJAYPIRCAApproved 2025-12-02: JAYPIRCA (NDA216059 SUPPL5)
2025-12-03FDA AdComheldAdCom 2025-12-03: Circulatory System Devices Panel of the Medical Devices Advisory Committee
2025-12-09Complete response lettercomplete responseSandoz Inc.CRL 2025-12-09: Sandoz Inc. BLA 761271
2025-12-09FDA approvalapprovedBEIGENETEVIMBRAApproved 2025-12-09: TEVIMBRA (BLA761232 SUPPL10)
2025-12-09FDA approvalapprovedBEIGENETEVIMBRAApproved 2025-12-09: TEVIMBRA (BLA761232 SUPPL9)
2025-12-09FDA approvalapprovedBEIGENETEVIMBRAApproved 2025-12-09: TEVIMBRA (BLA761232 SUPPL13)
2025-12-09FDA approvalapprovedMSD MERCK CORECARBRIOApproved 2025-12-09: RECARBRIO (NDA212819 SUPPL8)
2025-12-11FDA approvalapprovedBIOCRYST BCRXORLADEYOApproved 2025-12-11: ORLADEYO (NDA219776 ORIG1)
2025-12-11FDA approvalapprovedACADIA PHARMS INC ACADDAYBUE STIXApproved 2025-12-11: DAYBUE STIX (NDA219884 ORIG1)
2025-12-11FDA approvalapprovedVIELA BIOUPLIZNAApproved 2025-12-11: UPLIZNA (BLA761142 SUPPL4)
2025-12-11FDA approvalapprovedGLAXOSMITHKLINEBLUJEPAApproved 2025-12-11: BLUJEPA (NDA218230 SUPPL1)
2025-12-12Complete response lettercomplete responseLIB Therapeutics, Inc.LerocholCRL 2025-12-12: LIB Therapeutics, Inc. BLA 761427/Original 2, BLA 761427 (Lerochol (lerodalcibep-liga) injection)
2025-12-12FDA approvalapprovedJANSSEN BIOTECHAKEEGAApproved 2025-12-12: AKEEGA (NDA216793 SUPPL1)
2025-12-12FDA approvalapprovedENTASIS THERAPNUZOLVENCEApproved 2025-12-12: NUZOLVENCE (NDA219491 ORIG1)
2025-12-12FDA approvalapprovedLIB THERAPEUTICS, INC.LEROCHOLApproved 2025-12-12: LEROCHOL (BLA761427 ORIG1)
2025-12-12FDA approvalapprovedSUN PHARMA GLOBALILUMYAApproved 2025-12-12: ILUMYA (BLA761067 SUPPL24)
2025-12-12FDA approvalapprovedMILESTONE PHARMS USA MISTCARDAMYSTApproved 2025-12-12: CARDAMYST (NDA218571 ORIG1)
2025-12-13FDA approvalapprovedSPROUT PHARMSADDYIApproved 2025-12-13: ADDYI (NDA022526 SUPPL13)
2025-12-15FDA approvalapprovedDAIICHI SANKYOENHERTUApproved 2025-12-15: ENHERTU (BLA761139 SUPPL38)
2025-12-16Complete response lettercomplete responseGlaxoSmithKline LLCExdensur lepemokimab-ulaaCRL 2025-12-16: GlaxoSmithKline LLC BLA 761458/Original 2, BLA 761458 (Exdensur lepemokimab-ulaa) injection)
2025-12-16FDA approvalapprovedIBSAVYBRIQUEApproved 2025-12-16: VYBRIQUE (NDA210858 ORIG1)
2025-12-16FDA approvalapprovedGLAXOSMITHKLINE LLCEXDENSURApproved 2025-12-16: EXDENSUR (BLA761458 ORIG1)
2025-12-17Complete response letterapproved sinceInfoRLife SAphenylephrine hydrochloride in sodium chlorideCRL 2025-12-17: InfoRLife SA NDA 215783 (phenylephrine hydrochloride in sodium chloride injection)
2025-12-17FDA approvalapprovedINCYTE CORP INCYZYNYZApproved 2025-12-17: ZYNYZ (BLA761334 SUPPL5)
2025-12-17FDA approvalapprovedJANSSEN BIOTECHRYBREVANT FASPROApproved 2025-12-17: RYBREVANT FASPRO (BLA761433 ORIG1)
2025-12-17FDA approvalapprovedPHARMAANDRUBRACAApproved 2025-12-17: RUBRACA (NDA209115 SUPPL15)
2025-12-17FDA approvalapprovedPHARMAANDRUBRACAApproved 2025-12-17: RUBRACA (NDA209115 SUPPL14)
2025-12-18FDA approvalapprovedABBVIE ABBVVRAYLARApproved 2025-12-18: VRAYLAR (NDA204370 SUPPL17)
2025-12-18FDA approvalapprovedABBVIE ABBVVRAYLARApproved 2025-12-18: VRAYLAR (NDA204370 SUPPL15)
2025-12-18FDA approvalapprovedABBVIE ABBVVRAYLARApproved 2025-12-18: VRAYLAR (NDA204370 SUPPL16)
2025-12-18FDA approvalapprovedABBVIE ABBVVRAYLARApproved 2025-12-18: VRAYLAR (NDA204370 SUPPL14)
2025-12-18FDA approvalapprovedFORMYCON AGNUFYMCOApproved 2025-12-18: NUFYMCO (BLA761473 ORIG1)
2025-12-19FDA approvalapprovedBOEHRINGER INGELHEIMJASCAYDApproved 2025-12-19: JASCAYD (NDA220449 ORIG1)
2025-12-19FDA approvalapprovedGENENTECH INCLUNSUMIO LUNSUMIO VELOApproved 2025-12-19: LUNSUMIO; LUNSUMIO VELO (BLA761263 SUPPL6)
2025-12-19FDA approvalapprovedSHIELD TXACCRUFERApproved 2025-12-19: ACCRUFER (NDA212320 SUPPL19)
2025-12-19FDA approvalapprovedELI LILLY AND CO LLYMOUNJARO MOUNJARO KWIKPENApproved 2025-12-19: MOUNJARO; MOUNJARO (AUTOINJECTOR); MOUNJARO KWIKPEN (NDA215866 SUPPL39)
2025-12-19FDA approvalapprovedIPSENBYLVAYApproved 2025-12-19: BYLVAY (NDA215498 SUPPL5)
2025-12-19FDA approvalapprovedAMNEAL PHARMS LLC AMRXBONCRESAApproved 2025-12-19: BONCRESA (BLA761456 ORIG1)
2025-12-19FDA approvalapprovedAMNEAL PHARMS LLC AMRXOZILTUSApproved 2025-12-19: OZILTUS (BLA761457 ORIG1)
2025-12-19FDA approvalapprovedCYTOKINETICS CYTKMYQORZOApproved 2025-12-19: MYQORZO (NDA219083 ORIG1)
2025-12-22Complete response lettercomplete responseMedicaSafe, Inc.CRL 2025-12-22: MedicaSafe, Inc. NDA 220184
2025-12-22FDA approvalapprovedSCPHARMACEUTICALSFUROSCIX FUROSCIX READYFLOWApproved 2025-12-22: FUROSCIX; FUROSCIX READYFLOW (AUTOINJECTOR) (NDA209988 SUPPL4)
2025-12-22FDA approvalapprovedNOVO NVOWEGOVYApproved 2025-12-22: WEGOVY (NDA218316 ORIG1)
2025-12-22FDA approvalapprovedRECKITT BENCKISER RBGLYMUCINEX 12HR COLD & FEVER MULTI-SYMPTOMApproved 2025-12-22: MUCINEX 12HR COLD & FEVER MULTI-SYMPTOM (NDA217338 ORIG1)
2025-12-23Complete response lettercomplete responseGenzyme Corporation© (tolebrutinib) tabletsCRL 2025-12-23: Genzyme Corporation NDA 219624 (© (tolebrutinib) tablets)
2025-12-23FDA approvalapprovedOMEROS CORP OMERYARTEMLEAApproved 2025-12-23: YARTEMLEA (BLA761152 ORIG1)
2025-12-23FDA approvalapprovedAGIOS PHARMS INC AGIOAQVESME PYRUKYNDApproved 2025-12-23: AQVESME; PYRUKYND (NDA216196 SUPPL3)
2025-12-23FDA approvalapprovedABLYNX NVCABLIVIApproved 2025-12-23: CABLIVI (BLA761112 SUPPL18)
2025-12-30Complete response lettercomplete responseOutlook Therapeutics, Inc. OTLKbevacizumab-vikgCRL 2025-12-30: Outlook Therapeutics, Inc. BLA 761320 (bevacizumab-vikg injection)
2025-12-30Complete response lettercomplete responseDr. Reddy’s Laboratories, Inc.AVT03CRL 2025-12-30: Dr. Reddy’s Laboratories, Inc. BLA 761471 (AVT03)
2025-12-30FDA approvalapprovedVANDA PHARMS INC VNDANEREUSApproved 2025-12-30: NEREUS (NDA220152 ORIG1)

Trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2025-12 est.P2US Oncology ResearchNCT00248287 PhII ICb With/Without Erbitux in MBC PtsMetastatic Breast Canceractive not recruiting154
2025-12 est.P3Cell>Point LLCNCT01394679 A Phase 3 Study of 99mTC-EC-DG SPECT/CT Versus PET/CT in Lung CancerLung Cancernot yet recruiting154
2025-12 est.P2Cell>Point LLCNCT01899833 Efficacy and Saftey Study of 99mTc-ECDG in the Evaluation of Coronary Artery Disease (CAD)Coronary Artery Diseasenot yet recruiting60
2025-12 est.P3Aesculap Biologics, LLCNCT01957722 NOVOCART®3D for Treatment of Articular Cartilage of the KneeArticular Cartilage of the Femoral Condyle Between 2-6cm2active not recruiting233
2025-12 est.P2Candel Therapeutics, Inc. CADLNCT02446093 Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic AdenocarcinomaBorderline Resectable Pancreatic Adenocarcinomaunknown54
2025-12 est.P3Precision Life Sciences Group DTILNCT02546102 Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in GlioblastomaGlioblastoma Multiformesuspended234
2025-12 est.P3Rakuten Medical, Inc.NCT03769506 ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of TherapyHead and Neck Canceractive not recruiting135
2025-12 est.P3Sellas Life Sciences Group SLSNCT04229979 Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2Acute Myeloid Leukemiaactive not recruiting127
2025-12 est.P2Intervene Immune, Inc.NCT04375657 Thymus Regeneration, Immunorestoration, and Insulin Mitigation Extension TrialEpigenetic Aging; Immunosenescencerecruiting85
2025-12 est.P3Green Valley (Shanghai) Pharmaceuticals Co., Ltd.NCT04520412 A Study of Sodium Oligomannate (GV-971) in Participants With Mild to Moderate Alzheimer's DiseaseAlzheimer Diseasesuspended2046
2025-12 est.P2Healios K.K.NCT04533464 MultiStem® for Treatment of Trauma Induced Multiple Organ Failure/Systemic Inflammatory Response SyndromeTrauma; Adult Stem Cellsunknown156
2025-12 est.P1/P2Karyopharm Therapeutics Inc KPTIQNCT04607772 Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLRelapsed or Refractory Diffuse Large B-Cell Lymphomawithdrawn
2025-12 est.P1/P2Shanghai HEP Pharmaceutical Co., Ltd.NCT04662164 A Study to Access the Efficacy in Type 2 Diabetes Mellitus on Stable MetforminType 2 Diabetes Patientswithdrawn
2025-12 est.P3CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT04716114 A Study of SKLB1028 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory (R/R) AML With FLT3-MutatedAcute Myeloid Leukemia (AML)unknown315
2025-12 est.P2Philogen S.p.A.NCT04733183 Efficacy and Safety of L19TNF in Previously Treated Patients with Advanced Stage or Metastatic Soft-tissue SarcomaSoft Tissue Sarcomaactive not recruiting98
2025-12 est.P2UBP Greater China (Shanghai) Co., LtdNCT04979975 Evaluating Safety and Efficacy of Repeat Doses of UB-621in Adult Patients With Recurrent Genital HerpesRecurrent Genital Herpesnot yet recruiting200
2025-12 est.P2Sichuan Baili Pharmaceutical Co., Ltd.NCT05020457 SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC.Non Small Cell Lung Canceractive not recruiting69
2025-12 est.P2/P3Sichuan Baili Pharmaceutical Co., Ltd.NCT05020769 SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer.Non-small Cell Lung Canceractive not recruiting14
2025-12 est.P2Sichuan Baili Pharmaceutical Co., Ltd.NCT05022654 SI-B001 Combined With Irinotecan in the Treatment of Recurrent Metastatic Esophageal Squamous Cell Carcinoma.Esophageal Squamous Cell Carcinomasactive not recruiting22
2025-12 est.P2Sichuan Baili Pharmaceutical Co., Ltd.NCT05044897 A Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in the Treatment of Recurrent and Metastatic HNSCCHead and Neck Squamous Cell Carcinomaactive not recruiting11
2025-12 est.P2/P3Taiwan Liposome CompanyNCT05161637 Phase 2/3 Study of TLC590 for Postsurgical Pain ManagementPostsurgical Pain Managementunknown415
2025-12 est.P1/P2Sichuan Baili Pharmaceutical Co., Ltd.NCT05192486 A Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL)Diffuse Large B-cell Lymphomaactive not recruiting12
2025-12 est.P1/P2Mabwell (Shanghai) Bioscience Co., Ltd.NCT05216965 A Clinical Study of 9MW2821 in Subjects With Advanced Malignant Solid TumorsSolid Tumorsunknown208
2025-12 est.P1/P2Salarius Pharmaceuticals, LLCNCT05266196 A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577)Ewing Sarcoma; Myxoid Liposarcoma; Desmoplastic Small Round Cell Tumor; Extraskeletal Myxoid Chondrounknown10
2025-12 est.P1/P2BiolingusNCT05268237 Safety, Tolerability and Preliminary Efficacy of Sublingual Liraglutide in Patients With Type 2 Diabetes MellitusDiabete Type 2recruiting15
2025-12 est.P1/P2Sorrento Therapeutics, Inc.NCT05308225 Study to Assess Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple MyelomaMultiple Myelomaunknown72
2025-12 est.P2/P3Kibow PharmaNCT05407389 Rollover Extension Clinical Trial To Evaluate The Long-Term Safety And Efficacy Of KT-301 (Formerly US-APR2020) In Subjects With CKD IV Completing The US-APR202Chronic Kidney Disease stage4suspended600
2025-12 est.P1/P2Eleusis TherapeuticsNCT05434156 ELE-101 Safety & Tolerability Study in Healthy Participants and Patients With DepressionHealthy Volunteers; Major Depressive Disorder; Depressionactive not recruiting84
2025-12 est.P2PhytoHealth CorporationNCT05440227 PG2 Injection for the Treatment of moderate-to Severe Fatigue in Breast Cancer PatientsCancer-related Fatiguerecruiting36
2025-12 est.P2BiocadNCT05445076 Study of the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of BCD-180 in Patients With Axial SpondyloarthritisAxial Spondyloarthritisactive not recruiting250
2025-12 est.P1/P2Sichuan Baili Pharmaceutical Co., Ltd.NCT05485753 A Study of GNC-038, a Tetra-specific Antibody, in Patients With Central Nervous System Lymphoma (PCNSL) and Relapsed or Refractory Secondary Central Nervous SysPrimary Central Nervous System Lymphoma; Secondary Central Nervous System Lymphomaactive not recruiting7
2025-12 est.P1/P2E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.NCT05525715 A Study of QY201 Tablet in Subjects With Moderate to Severe Atopic DermatitisAtopic Dermatitisunknown260
2025-12 est.P1/P2Sichuan Baili Pharmaceutical Co., Ltd.NCT05627856 A Study of GNC-038 Injection in Patients With Relapsed or Refractory NK/ T-cell Lymphoma, AITL, and Other NHLNK/T Cell Lymphoma; Vascular Immunomother T Cell Lymphoma; Non-Hodgkin Lymphomaactive not recruiting4
2025-12 est.P3IBSA Institut Biochimique SANCT05632783 TreatMent Of Knee osTeoarthritis wIth chONdroitin Sulfate - the OA MOTION StudyKnee Osteoarthritiswithdrawn
2025-12 est.P2RemeGen Co., Ltd.NCT05680480 A Study of Telitacicept in Lupus NephritisLupus Nephritisunknown120
2025-12 est.P2Omeros Corporation OMERNCT05855083 Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMAThrombotic Microangiopathies; Hematopoietic Stem Cell Transplantationrecruiting18
2025-12 est.P1/P2HuidaGene Therapeutics Co., Ltd.NCT05906953 Safety and Efficacy Trial of HG004 for Leber Congenital Amaurosis Related to Rpe65 Gene Mutations (STAR)Leber Congenital Amaurosis; Inherited Retinal Diseases Caused by RPE65 Mutationsunknown20
2025-12 est.P1/P2Sichuan Baili Pharmaceutical Co., Ltd.NCT05944978 A Study of GNC-035 in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological MalignanciesRelapsed/Refractory Chronic Lymphocytic Leukemiaactive not recruiting3
2025-12 est.P1/P2Sichuan Baili Pharmaceutical Co., Ltd.NCT05949619 A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid TumorsNon-small Cell Lung Canceractive not recruiting14
2025-12 est.P1/P2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT05959694 A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic LyChronic Lymphocytic Leukemia; Small Lymphocytic Lymphomaunknown107
2025-12 est.P2Glaukos Corporation GKOSNCT05966493 A Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With PCEDPersistent Corneal Epithelial Defectrecruiting84
2025-12 est.P1/P2CNBG-Virogin Biotech (Shanghai) Ltd.NCT06008925 Clinical Study of VG161 Combined With Nivolumab Injection in Patients With Advanced Metastatic Gastric CancerMetastatic Gastric Cancerunknown43
2025-12 est.P1/P2Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT06092268 A Phase IB/II Clinical Study of SHR-A2009 for Injection in Combination With Other Antitumor Therapies in Patients With Advanced Solid TumorsAdvanced Solid Tumorsunknown270
2025-12 est.P1/P2Shanghai Hengrui Pharmaceutical Co., Ltd.NCT06104553 A Trial of SHR-A1912 Combined With Other Therapies in B-cell Non-Hodgkin 's LymphomaB-cell Non-Hodgkin's Lymphomaunknown132
2025-12 est.P1/P2Affini-T Therapeutics, Inc.NCT06105021 Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid TumorPancreatic Ductal Adenocarcinoma; Non-Small Cell Lung Cancer; Colorectal Cancer; Solid Tumor; KRAS Gactive not recruiting100
2025-12 est.P3Clinuvel, Inc. CUVLNCT06109649 A Study to Compare the Efficacy and Safety of SCENESSE and Narrow-Band Ultraviolet (NB-UVB) Light Versus NB-UVB Light Alone in Patients With VitiligoVitiligoactive not recruiting200
2025-12 est.P3Shanghai Yizhong Pharmaceutical Co., Ltd.NCT06143553 Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast CancerMetastatic Breast Cancer (MBC)unknown168
2025-12 est.P1/P2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT06150014 A Clinical Study of TQA3605 Tablets Monotherapy or in Combination With Nucleoside (Acid) Analogues in Treatment Naive and Treated Patients With Chronic HepatitiChronic Hepatitis bactive not recruiting88
2025-12 est.P1/P2iRegene Therapeutics Co., Ltd.NCT06167681 The Safety, Tolerability and Efficacy of NouvNeu001 for Parkinson's DiseaseParkinson Diseaserecruiting40
2025-12 est.P1/P2BiocadNCT06185335 A Trial of the Safety and Efficacy of Single-Dose Administration of ANB-010 in Subjects With Hemophilia AHemophilia Aactive not recruiting50
2025-12 est.P2RemeGen Co., Ltd.NCT06227117 Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast CancerBreast Cancerrecruiting120
2025-12 est.P2RemeGen Co., Ltd.NCT06227156 Disitamab Vedotin in the Treatment With HER2- Expression, Subjects With Locally Advanced or Metastatic Castration-resistant Prostate CancerCastration-resistant Prostate Cancerunknown40
2025-12 est.P2Rege Nephro Co., Ltd.NCT06289998 Study of Tamibarotene in Patients With ADPKDAutosomal Dominant Polycystic Kidney Disease (ADPKD)active not recruiting70
2025-12 est.P3CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT06313086 DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast CancerHER2-positive Breast Cancerrecruiting442
2025-12 est.P3Tianjin Hemay Pharmaceutical Co., LtdNCT06313983 A Phase Ⅲ Study of Hemay022 in Combination With AI In Advanced Breast CancerBreast Cancerrecruiting339
2025-12 est.P1/P2Jiangsu HengRui Medicine Co., Ltd.NCT06385678 A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D MutationAdvanced KRAS G12D Mutant Solid Tumorsactive not recruiting47
2025-12 est.P2PHARMENTERPRISES LLCNCT06391164 Study to Evaluate the Efficacy and Safety of XC243 in Patients With Exacerbation of Chronic CystitisCystitisunknown280
2025-12 est.P2SpinogenixNCT06427668 Study of SPG302 in Adult Participants With Mild-to-Moderate Alzheimer's Disease (AD)Alzheimer Diseaseactive not recruiting24
2025-12 est.P3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT06434467 The Efficacy and Safety of Nelarabine Injection in Patients With T-lymphoblastic Leukemia and T-lymphoblastic LymphomaT-lymphoblastic Leukemia; T-lymphoblastic Lymphomaunknown83
2025-12 est.P1/P2Shanghai Hengrui Pharmaceutical Co., Ltd.NCT06439589 Phase Ib/II Study of HRS2398 in Combination With Adebrelimab in Patients With Advanced Solid TumorsAdvanced Solid Tumorsunknown88
2025-12 est.P2Fujian Shengdi Pharmaceutical Co., Ltd.NCT06565871 A Study of HRS9531 Injection in Obese Subjects With Obstructive Sleep ApneaWeight Managementunknown108
2025-12 est.P2Fujian Shengdi Pharmaceutical Co., Ltd.NCT06595797 A Multicenter, Randomized, Double-blind, Placebo-parallel-controlled Phase II Clinical Study Evaluating the Efficacy and Safety of HRS9531 Injection in Obese SuObese Subjects With Polycystic Ovary Syndrome (PCOS)unknown144
2025-12 est.P3Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. SBFMNCT06639295 A Study to Evaluate 611 in Patients With Chronic Rhinosinusitis With Nasal PolypsSinusitis; Nasal Polypsactive not recruiting243
2025-12 est.P3BiocadNCT06640530 Clinical Study of the Efficacy and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the SkinAdvanced Melanoma; Melanoma (Skin)active not recruiting392
2025-12 est.P2SynAct Pharma ApsNCT06671054 A Dose Response Study to Evaluate the Efficacy and Safety of Oral AP1189 Administered in Disease-Modifying Anti-Rheumatic Drug (DMARD) naïve Participants ParticRheumatoid Arthritis (RA)recruiting240
2025-12 est.P2Gilead Sciences GILDNCT06682234 Study of Obeldesivir as Postexposure Prophylaxis for Filovirus Diseases Virus DiseaseFilovirus Disease; Postexposure Prophylaxis for Filovirus Diseasewithdrawn
2025-12 est.P2Verastem, Inc. VSTMNCT06682572 A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese PatientsLow Grade Serous Ovarian Cancer; Ovarian Canceractive not recruiting16
2025-12 est.P1/P2Zhuhai Beihai Biotech Co., LtdNCT06732531 Safety, Tolerability, and Preliminary Efficacy of BH011 in Subjects With Non-Muscle-Invasive Bladder CancerBladder Cancer; Non Muscle Invasiverecruiting48
2025-12 est.P1/P2Herbarium Laboratorio Botanico LtdaNCT06751433 Evaluation of Clinical, Perceived and Instrumental Efficacy of a Scar Gel in Preventing Hypertrophic ScarsAcceptability Study; Real-use Conditions; Safety and Efficacy; Topical Administration; Hypertrophic recruiting80
2025-12 est.P2Zhuhai Rui-Inno Pharmaceutical Technology Co., Ltd.NCT06852976 A Phase 2a Proof of Concept Open-Label, Randomized, Controlled Study to Evaluate the Safety and Efficacy of MDI-1228-mesylate Gel Compared With Standard of CareDiabetic Foot Ulcerrecruiting60
2025-12 est.P2Jina Pharmaceuticals Inc.NCT06867042 Tacrolimus Lipid Suspension for Enema in Adult Subjects with Mild to Moderately Active Left-sided/Distal Ulcerative Colitis Who Had an Inadequate Response to thUlcerative Colitis (UC); Ulcerative Colitis, Active Moderatenot yet recruiting150
2025-12 est.P3Jina Pharmaceuticals Inc.NCT06867562 Paclitaxel Lipid Suspension for Patients with Platinum-Resistant /Refractory Ovarian CancerPlatinum-Resistant Primary Peritoneal Carcinoma; Platinum Resistant High Grade Epithelial Ovarian Canot yet recruiting166
2025-12 est.P1/P2STCube, Inc.NCT06873763 Nelmastobart in Combination With Trifluridine/ Tipiracil and Bevacizumab in Metastatic/ Recurrent Colorectal CancerMetastatic Colorectal Cancer (CRC); Recurrent Colorectal Cancerrecruiting52
2025-12 est.P1/P2Shenyang Sunshine Pharmaceutical Co., LTD.NCT07008703 Phase I Study of sss40 Injection for Moderate-to-Severe Bone Metastatic Cancer PainCancer Painrecruiting132
2025-12 est.P2Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT07028268 A Trial of SHR-2017 Injection in Patients With Bone Metastases From Solid TumorsFor Prevention of Bone Events in Patients With Bone Metastases From Solid Tumorsrecruiting210
2025-12 est.P2BiocadNCT07108309 BCD-236 in Combination With Chemotherapy in Patients With Relapsed and/or Metastatic Triple Negative Breast CancerTriple Negative Breast Cancerrecruiting124
2025-12 est.P2Beijing Suncadia Pharmaceuticals Co., LtdNCT07133815 Evaluate the Long-term Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial HypercholesterolemiaHomozygous Familial Hypercholesterolemianot yet recruiting55
2025-12 est.P2Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.NCT07147049 Evaluate the Safety and Efficacy of HL-1186 Tablet for Moderate to Severe Acute Pain After SurgeryModerate to Severe Acute Postoperative Painrecruiting72
2025-12 est.P2Grand Theravac Life Sciences (Nanjing) Co., Ltd.NCT07179653 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of TVAX-008 Injection in Chronic HepatitHBV Infectionactive not recruiting48
2025-12-01P3BeiGeneNCT03519230 Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian CancerOvarian Canceractive not recruiting224
2025-12-01P3AbbVie ABBVNCT04760769 Open-label Trial in Parkinson's Disease (PD)Parkinson Diseasecompleted992
2025-12-01 est.P2Khondrion BVNCT04846036 The KHENERGYC StudyMitochondrial Diseases; Mitochondrial DNA tRNALeu(UUR) m.3243A<G Mutation; MELAS; Subacute Necrotizisuspended24
2025-12-01 est.P1/P2Ectin Research ABNCT05390645 A Study of MFA-370 in Patients with Metastatic Urothelial CancerMetastatic Urothelial Cancerwithdrawn
2025-12-01P1/P2SignalChem Lifesciences CorporationNCT05860296 Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung CancersLung Cancer, Nonsmall Cell; Lung Cancer Stage IV; Lung Cancer Metastaticterminated36
2025-12-01 est.P2RemeGen Co., Ltd.NCT05943379 RC48-ADC in Combination With Gemcitabine in High Risk NMIBC SubjectsNMIBCrecruiting85
2025-12-01 est.P2/P3Jiangsu HengRui Medicine Co., Ltd.NCT05945901 A Phase II/III Study of HR070803 in Combination With Oxaliplatin, 5-fluorouracil, Calcium Folinate and Bevacizumab Versus FOLFOX in Combination With BevacizumabColorectal Canceractive not recruiting669
2025-12-01P2Shuttle Pharmaceuticals, Inc. SHPHNCT06359379 Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT PromoterGlioblastoma, IDH-wildtypeterminated30
2025-12-01 est.P2Distribuidora Biolife SA de CVNCT06520878 Impact of NANO-PSO on Cognition in Older Adults with Mild to Moderate Cognitive ImpairmentCognitionrecruiting60
2025-12-01P1/P2Fenix Innovation GroupNCT06621043 Assessing the Safety and Efficacy of Full-Spectrum Medicinal Cannabis Plant Extract 0.08% THC (NTI164) in the Treatment of Rett Syndrome (RTT)Rett Syndromecompleted14
2025-12-01P1/P2Fenix Innovation GroupNCT06621888 Investigating The Effects Of Full-Spectrum Medicinal Cannabis Plant Extract 0.08% THC (NTI164) On Paediatric Acute-onset Neuropsychiatric Syndrome (PANS)PANS Pediatric Acute-Onset Neuropsychiatric Syndromecompleted18
2025-12-01 est.P2Hansoh BioMedical R&D CompanyNCT06635772 A Study of the Effect and Safety of HS-10390 in the Treatment of Patients with Primary IgA NephropathyImmunoglobulin a Nephropathyunknown90
2025-12-01 est.P1/P2Biosergen ASNCT06678113 Study to Assess the Safety and Efficacy of Intravenous BSG005 in Patients With Invasive Fungal InfectionInvasive Fungal Infectionunknown15
2025-12-01P2Guangdong Hengrui Pharmaceutical Co., LtdNCT07091357 A Clinical Study on the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of SHR-1819 Injection in Patients With Seasonal Allergic RhinitisSeasonal Allergic Rhinitiscompleted108
2025-12-02P1/P2Synthorx, Inc, a Sanofi companyNCT04009681 A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707-101)Metastasisterminated175
2025-12-02P1/P2Ascendis Pharma Oncology Division A/S ASNDNCT04799054 A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid TumorsAdvanced Solid Tumor; Locally Advanced Solid Tumor; Metastatic Solid Tumor; Head and Neck Squamous Cterminated188
2025-12-02P2Hoffmann-La RocheNCT05630066 A Study to Investigate the Pharmacokinetics (PK) and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With AngelAngelman Syndromecompleted48
2025-12-02P2Allodynic Therapeutics, IncNCT05685225 Single-Site Study of Naltrexone/Acetaminophen for the Acute Treatment of Migraine: A Phase 2 Randomized TrialMigrainewithdrawn
2025-12-02P3Boehringer IngelheimNCT06066515 A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose WeightObesitycompleted726
2025-12-03P2AGO Research GmbHNCT04274426 Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian CancerRecurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinomaactive not recruiting136
2025-12-03P2/P3Immunome, Inc. IMNMNCT04871282 A Study of AL102 in Patients With Progressing Desmoid TumorsDesmoid; Desmoid Tumoractive not recruiting198
2025-12-03P1/P2Bristol-Myers Squibb BMYNCT05255601 A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Lymphoma, Non-Hodgkin; Hodgkin Diseaseterminated5
2025-12-03P3Boehringer IngelheimNCT06176365 A Study to Test Whether Survodutide Helps Japanese People Living With Obesity DiseaseObesitycompleted274
2025-12-03P1/P2Therapex Co., LtdNCT06186076 A Study to Investigate Safety, Tolerability, PK and Anti-tumor Activity of TRX-221 in EGFRm NSCLC PatientsCarcinoma, Non-Small-Cell Lung; EGFR Mutant Advanced Non-Small Cell Lung Cancerterminated19
2025-12-03P2AstraZeneca AZNNCT06595238 A Study in Participants With Obesity or Overweight With at Least One Weight-related ComorbidityObesity or Overweightcompleted262
2025-12-03P2Guangdong Hengrui Pharmaceutical Co., LtdNCT06786455 Pharmacokinetics, Pharmacodynamics, Safety, and Preliminary Efficacy of Subcutaneous Injection of SHR-1905 in Adolescent Asthmatic Subjects - an Open-label, SinAdolescent Asthmacompleted9
2025-12-03P2PHARMAFINANCT07131657 Ropiclobet for Regional Anesthesia and Post-Operative Pain Control in Upper Extremity SurgeryNerve Block; Upper Extremity Surgerycompleted40
2025-12-04P3Eli Lilly and Company LLYNCT04396574 A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With MigraineMigraineterminated558
2025-12-04P2Sustained Therapeutics Inc.NCT05707208 A Randomized, Controlled Study of Repeat Dose Sustained Release Lidocaine for Treatment of Chronic Scrotal PainChronic Paincompleted63
2025-12-04P3Sanofi Pasteur, a Sanofi Company SNYNCT06252285 Efficacy, Immunogenicity, and Safety Study of a Respiratory Syncytial Virus Vaccine in Infants and ToddlersRSV Immunisationterminated6300
2025-12-04P2Arcutis Biotherapeutics, Inc. ARQTNCT06998056 Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic DermatitisAtopic Dermatitis (Eczema)completed101
2025-12-05P1/P2Dragonfly Therapeutics DFLINCT04143711 Study of DF1001 in Patients With Advanced Solid TumorsSolid Tumor, Adultcompleted270
2025-12-05 est.P3Xuanzhu Biopharmaceutical Co., Ltd.NCT05257395 A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast CancerAdvanced Breast Canceractive not recruiting397
2025-12-05P1/P2Merck Sharp & Dohme LLC MRKNCT05342636 A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)Esophageal Squamous Cell Carcinoma (ESCC)completed90
2025-12-05P2Shanghai Hengrui Pharmaceutical Co., Ltd.NCT05593250 A Trial of SHR-1905 in Subjects With Severe Uncontrolled AsthmaAsthmacompleted260
2025-12-05P3AbbVie ABBVNCT05818709 A Study to Assess Adverse Events and Effectiveness of HAC 22L Injection for Mid-Face Volume in Adult ParticipantsFacial Volume Deficitcompleted61
2025-12-06P2Shanghai Haiyan Pharmaceutical Technology Co., Ltd.NCT06901830 A Study of YZJ-4729 Tartrate Injection for the Treatment of Pain After Orthopedic SurgeryPaincompleted150
2025-12-07P3Foresee Pharmaceuticals Co., Ltd.NCT05493709 Efficacy, Safety, and Pharmacokinetics of Leuprolide Mesylate in Subjects With Central Precocious PubertyPuberty; Precocious, Centralcompleted94
2025-12-07P2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT06706310 Evaluate TQ-A3334 Combined Nucleoside (Acid) Analogs in the First Treatment/Treatment of Chronic HBV InfectionChronic Hepatitis Bactive not recruiting116
2025-12-08P3Areteia TherapeuticsNCT05763121 A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma.Eosinophilic Asthma; Asthma; Eosinophilic; Asthmaterminated1061
2025-12-08P3Areteia TherapeuticsNCT05813288 A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3)Eosinophilic Asthma; Asthma; Eosinophilic; Asthmaterminated654
2025-12-08P2Eli Lilly and Company LLYNCT05848258 An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid ArthritisRheumatoid Arthritiscompleted164
2025-12-08P3Novo Nordisk A/S NVONCT06131437 A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose WeightObesitycompleted809
2025-12-08P3Areteia TherapeuticsNCT06388889 Phase III Long-Term Extension Study With DexpramipexoleEosinophilic Asthmaterminated509
2025-12-08P2Carmot Therapeutics, Inc.NCT06525935 A Study of Enicepatide (CT-388) in Participants With Obesity or Overweight With at Least One Weight-Related ComorbidityObesity; Overweightcompleted469
2025-12-08P1/P2Sinovac Life Sciences Co., Ltd.NCT06939777 Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SNA02-48 Injection in Chinese Adult ParticipantsTetanuscompleted255
2025-12-08P2Ascletis Pharma (China) Co., LimitedNCT07002905 A Study to Evaluate the Efficacy, Safety, and Tolerability in Participants With Obesity or Overweight With Weight-Related ComorbiditiesChronic Weight Managementcompleted125
2025-12-09P2Takeda TAKNCT04530123 Dose-Ranging Study of the Efficacy and Safety of TAK-101 for Prevention of Gluten-Specific T Cell Activation in Participants With Celiac Disease on a Gluten-FreCeliac Diseasecompleted102
2025-12-09P2Chiesi Farmaceutici S.p.A.NCT06029595 Efficacy and Safety of Tanimilast in Asthmatics uNcontrolled on ICS-containinG backgrOund Maintenance TherapyUncontrolled Asthmaterminated517
2025-12-09P3Rose Research Center, LLCNCT06554873 Adaptive Use of Nicotine Substitution to Maintain Smoking Reduction/Abstinence in Nicotine RespondersSmoking Cessation; Harm Reductioncompleted150
2025-12-10P3Eli Lilly and Company LLYNCT04616326 A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic MigraineChronic Migraineactive not recruiting312
2025-12-10P3Otsuka Pharmaceutical Development & Commercialization, Inc.NCT04786574 A Study to See if Tolvaptan Can Delay Dialysis in Infants and Children Who at Enrollment Are 28 Days to Less Than 12 Weeks Old With Autosomal Recessive PolycystAutosomal Recessive Polycystic Kidney Disease (ARPKD)withdrawn
2025-12-10 est.P3Swedish Orphan BiovitrumNCT05814159 A Study of Anakinra in Japanese Patients With Still's Disease (SJIA and AOSD)Still's Disease, Juvenile Onset; Still's Disease, Adult-Onsetactive not recruiting15
2025-12-10P1/P2S.Biomedics Co., Ltd.NCT05887466 Study to Evaluate the Safety and Efficacy of ESC-derived Dopamine Progenitor Cell Therapy in PD PatientsParkinson's Diseasecompleted12
2025-12-10P2atai Therapeutics, Inc.NCT06693609 Exploratory Safety and Efficacy of EMP-01 in Social Anxiety DisorderSocial Anxiety Disordercompleted70
2025-12-11P3Colgate Palmolive CLNCT07134231 Clinical Study to Evaluate the Anti-cavity Efficacy of Three Dentifrices: An In Situ ModelDemineralization; Remineralization; Dental Cavity; Enamel Lesionscompleted36
2025-12-12 est.P2ONYNCT04056741 Administration of Surfactant Through an Instillation Device Infasurf® (Calfactant) in Neonates- A Pilot StudyRDS of Prematurity; Surfactant Protein B Deficiency; Chronic Lung Diseasesuspended55
2025-12-12 est.P2Hansoh BioMedical R&D CompanyNCT06007729 ARTEMIS-006: HS-20093 in Patients With Head and Neck Squamous Cell Carcinoma and Other Solid TumorsHead and Neck Squamous Cell Carcinomarecruiting170
2025-12-12P3Boehringer IngelheimNCT06058793 Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated LiposarcomaLiposarcoma, Dedifferentiatedcompleted138
2025-12-12P3Boehringer IngelheimNCT06066528 A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose WeightObesity; Diabetes Mellitus, Type 2completed755
2025-12-12 est.P2Shanghai Jiatan Pharmatech Co., LtdNCT06124963 A Study of WX390 Combined With Toripalimab in Patients With Advanced Gastric-type Endocervical Adenocarcinoma With STK11 MutationsGastric Type Adenocarcinoma (GAS) With STK11 Mutationrecruiting20
2025-12-12P2Haisco Pharmaceutical Group Co., Ltd.NCT06168383 To Evaluate the Efficacy and Safety of HSK31679 in Chinese Patients With Non-Alcoholic Steatohepatitis (NASH) .Non-Alcoholic Steatohepatitis (NASH)completed186
2025-12-12P3Apellis Pharmaceuticals, Inc.NCT07214740 Study to Evaluate a Pegcetacoplan (Syfovre®) Prefilled SyringeGeographic Atrophy Secondary to Age-related Macular Degenerationcompleted44
2025-12-15P2TYK Medicines, IncNCT05948813 TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain MetastasesNSCLC; EGFR Activating Mutation; Brain Metastasesrecruiting420
2025-12-15 est.P2Suzhou Alphamab Co., Ltd.NCT06180889 Factor XI inhibiTion for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee ArthroplastyKnee Arthroplasty, Totalactive not recruiting241
2025-12-15P3argenx ARGXNCT06307613 A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye DiseaseThyroid Eye Diseaseterminated102
2025-12-15P3argenx ARGXNCT06307626 A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease.Thyroid Eye Diseaseterminated105
2025-12-15P2Eli Lilly and Company LLYNCT06373146 A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With ObesityObesitycompleted392
2025-12-15P2Guangzhou Chia Tai Innovative Pharmaceutical Co., Ltd.NCT06532578 Evaluate the Safety and Efficacy of CPX101 in Overweight and Obese Subjects Without Diabetes MellitusOverweight and Obesitycompleted240
2025-12-15P1/P2NexThera Co., Ltd.NCT06704009 NT-101 Topical Ophthalmic Solution in Patients With Wet AMDWet Age Related Macular Degeneration; Wet AMDcompleted20
2025-12-15P2Motric BioNCT06830642 Study of the Oral Treatment MTR-601 in Cervical DystoniaCervical Dystoniaterminated38
2025-12-15P2Chendu DIAO Pharmaceutical Group CO., LTD.NCT06953063 A Study to Evaluate the Efficacy and Safety of DA-302168S Tablets in Overweight/Obese SubjectsOverweight and Obesitycompleted250
2025-12-15P3GlaxoSmithKlineNCT06995430 A Phase 3 Study to Assess the Immune Response and Safety of rMenB+OMV NZ in Primed Healthy Participants (10 to 20 Years Old)Meningitiscompleted312
2025-12-15 est.P2Shin Poong Pharmaceutical Co. Ltd.NCT07064525 Evaluate the Efficacy and Safety of SPC1001 Low in Patients With Essential HypertensionHypertension (HTN); NYHA Class III Heart Failure; NYHA Class IV Heart Failure; Diabete Mellitusenrolling by invitation252
2025-12-16P2Pfizer PFENCT04821310 Protonix Treatment of Maintenance of Healing in Pediatric Participants Aged 1-11 Years and 12-17 YearsEsophagitisterminated43
2025-12-16P2CyanVac LLCNCT05736835 A Phase 2 Trial of the Immunogenicity and Safety of CVXGA Intranasal COVID Vaccine in Healthy AdultsCOVID-19completed227
2025-12-16P2Upstream Bio Inc. UPBNCT06196879 A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT)Severe Asthmacompleted479
2025-12-16P1/P2Innovent Biologics (Suzhou) Co. Ltd.NCT06198426 A Study of IBI3004 in Subjects With Unresectable, Locally Advanced or Metastatic Solid TumorsSolid Tumorterminated5
2025-12-16P3Hoffmann-La RocheNCT06267001 A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have ReNon-small Cell Lung Cancer (NSCLC)terminated56
2025-12-16P2GlaceumNCT06329141 A Study to Assess the Efficacy and Safety of Vutiglabridin in Early Parkinson's Disease PatientsParkinson Diseasecompleted99
2025-12-16P2Zai Lab (Hong Kong), Ltd.NCT06380907 A Phase 2 Study of ZL-1102 in Patients With Chronic Plaque PsoriasisPlaque Psoriasisterminated65
2025-12-16P2New England Cell Therapeutics, Inc.NCT06910384 A Study of STRO4 in Patients Amyotrophic Lateral Sclerosis (ALS)Amyotrophic Lateral Sclerosisterminated1
2025-12-16P2Pfizer PFENCT06973720 A Phase 2b Study to Evaluate the Efficacy and Safety of Once-Monthly MET097 in Adults With Obesity or OverweightObesity; Overweight or Obesitycompleted268
2025-12-17P3Sanofi SNYNCT05206773 A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry DiseaseFabry Diseaseactive not recruiting122
2025-12-17P3Bellus Health Inc. - a GSK companyNCT05599191 A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic CoughCough; Refractory Chronic Coughcompleted957
2025-12-17P2Gilead Sciences GILDNCT05629208 Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)Cutaneous Lupus Erythematosus (CLE)terminated20
2025-12-17P3Quince Therapeutics S.p.A.NCT06193200 Evaluate the Neurological Effects of EryDex on Subjects With A-TAtaxia Telangiectasiacompleted105
2025-12-17P2Mineralys Therapeutics Inc. MLYSNCT06785454 A Study to Assess the Efficacy and Safety of Lorundrostat in Participants With Obstructive Sleep Apnea and HypertensionObstructive Sleep Apnea; Hypertensioncompleted48
2025-12-17P1/P2BioNTech SE BNTXNCT06821061 A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy PeopleInfluenza; COVID-19 (Coronavirus Disease 2019)completed2650
2025-12-18P3QED Therapeutics, a BridgeBio companyNCT06164951 A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With AchondroplasiaAchondroplasiacompleted114
2025-12-18P2OrphalanNCT07010575 Patient Preference Study: Standard of Care Versus Once-daily Trientine TetrahydrochlorideWilson's Diseasecompleted10
2025-12-19P3Rhythm Pharmaceuticals, Inc. RYTMNCT05093634 EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R PathwayObesity; Genetic Obesitycompleted296
2025-12-19P1/P2Lyvgen Biopharma Holdings LimitedNCT05301764 A Study of LVGN6051 Combined With Anlotinib in Patient With Soft Tissue SarcomaSoft Tissue Sarcomacompleted39
2025-12-19P2BeiGeneNCT05635708 A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung CancerNon-small Cell Lung Cancer; Metastatic Non-small Cell Lung Cancercompleted418
2025-12-19P1/P2Sinovac Biotech Co., Ltd SVANCT06063057 Inactivated Bivalent Enterovirus Vaccine (Vero Cell) Phase I/II Clinical TrialHand, Foot and Mouth Disease; Herpanginacompleted744
2025-12-19P2Reveal Pharmaceuticals Inc.NCT06322342 Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast AgentCentral Nervous System (CNS) Lesions; Brain Metastases; Brain Neoplasms; Brain Neoplasms, Benign; Brcompleted18
2025-12-19P3ACADIA Pharmaceuticals Inc. ACADNCT06420297 OLE Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi SyndromeHyperphagia in Prader-Willi Syndrometerminated168
2025-12-19P2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT06439381 Long-term Safety and Efficacy of TQH2722 Injection in the Treatment of Chronic Sinusitis With or Without Nasal PolypsChronic Rhinosinusitiscompleted119
2025-12-19P3Boston Scientific Corporation BSXNCT06492174 A Clinical Trial to Assess the Agent Paclitaxel Coated PTCA Balloon Catheter for the Treatment of Subjects With In-Stent Restenosis (ISR) - Long Lesion CohortIn-Stent Restenosisactive not recruiting20
2025-12-19P2AstraZeneca AZNNCT06579105 Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus.Diabetes Mellitus, Type 2completed406
2025-12-19 est.P1/P2AstraZeneca AZNNCT07060365 A Master Protocol Study to Investigate Biomarker-guided Novel Anticancer Agent(s) as Monotherapy or Combination Therapy in Participants With Advanced/Recurrent Advanced/Recurrent Ovarian Cancerwithdrawn
2025-12-19P2E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.NCT07712536 Phase IIa Study of Pharmacokinetics, Safety and Efficacy of QY201 Tablets in Adolescent Subjects With Moderate to Severe Atopic DermatitisAdolescent Participants With Moderate to Severe Atopic Dermatitis (AD)completed24
2025-12-20 est.P2RemeGen Co., Ltd.NCT06105008 Study of Disitamab Vedotin With Toripalimab Verus Disitamab Vedotin in Hormone Receptor Positive, HER2-low Locally Advanced or Metastatic Breast CancerBreast Neoplasmswithdrawn
2025-12-20 est.P2Guangdong Raynovent Biotech Co., LtdNCT06254261 A Study of RAY1225 in Participants With ObesityObesityrecruiting270
2025-12-20P2Haisco Pharmaceutical Group Co., Ltd.NCT06670352 Phase II Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgANIgA Nephropathy (IgAN)completed87
2025-12-21P3Colgate Palmolive CLNCT07225478 Clinical Study to Evaluate the Tooth Whitening Efficacy of a New NextGen In-office Whitening SystemHealth Adult Subjectscompleted180
2025-12-22P3Pfizer PFENCT03422822 Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic DermDermatitis, Atopiccompleted3166
2025-12-22P3Merck Sharp & Dohme LLC MRKNCT04193215 V114 and Acute Otitis Media (V114-032/PNEU-ERA)Acute Otitis Media (AOM)completed7119
2025-12-22P3Hoffmann-La RocheNCT04629248 A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous NephropathyPrimary Membranous Nephropathyactive not recruiting142
2025-12-22P1/P2BioNTech SE BNTXNCT05262530 Safety and Preliminary Efficacy Trial of BNT142 in Patients With CLDN6-positive Solid TumorsSolid Tumorterminated73
2025-12-22P1/P2Sanofi SNYNCT05450562 Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid TumorsNeoplasmterminated33
2025-12-22P2Sanofi SNYNCT05704049 A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Relapsed/Refractory Multiple Myelomaactive not recruiting118
2025-12-22 est.P3Shanghai Jiatan Pharmatech Co., LtdNCT05824871 A Phase III Study of Oral Sudapyridine (WX-081) Tablets in Rifampicin-Resistant Pulmonary Tuberculosis PatientsRifampin-Resistant Pulmonary Tuberculosis; Tuberculosis, Multidrug-Resistant (MDR-TB)recruiting450
2025-12-22 est.P1/P2IDP Discovery Pharma S.L.NCT05908409 A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic MalignanciesMultiple Myeloma (MM); Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; Double Hit Lymphoma; recruiting37
2025-12-22P1/P2Kyverna Therapeutics KYTXNCT06342960 KYSA-3: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus NephritisLupus Nephritis; Lupus Nephritis - WHO Class III; Lupus Nephritis - WHO Class IVterminated2
2025-12-22P2HysensBio Co., LtdNCT06464939 Phase 2 Study of KH001 in Long-term Relief From Dentin HypersensitivityDentin Hypersensitivitycompleted120
2025-12-22P3AmzellNCT06693648 A Study to Evaluate Efficacy and Safety of AMZ001 for the Treatment of Knee Osteoarthritis SymptomsOsteoarthritis of Knee; Osteoarthritis, Kneecompleted549
2025-12-22P2Enyo PharmaNCT06939816 Vonafexor in Patients With Impaired Renal Function and Suspected MASH (Metabolic Dysfunction-associated Steatohepatitis)Chronic Kidney Disease Stage 2; Chronic Kidney Disease Stage 3; Metabolic Dysfunction-Associated Steterminated10
2025-12-22P3Guangdong Raynovent Biotech Co., LtdNCT07229820 Efficacy and Safety of ZSP1273 in Adolecent 12-17 Years Old With Influenza AInfluenza Acompleted157
2025-12-23P3X4 Pharmaceuticals XFORNCT03995108 Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) SyndromeWHIM Syndromecompleted31
2025-12-23P3Chiesi Farmaceutici S.p.A.NCT04636814 A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as Chronic Obstructive Pulmonary Diseaseterminated3973
2025-12-23P3SynOx Therapeutics LimitedNCT05417789 Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT)TGCTactive not recruiting128
2025-12-23P3Biocon Biologics UK LtdNCT06038539 Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as NHR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patientsterminated55
2025-12-23P3Amgen AMGNNCT06248619 A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active ThyroThyroid Eye Diseaseactive not recruiting89
2025-12-23P3Haisco Pharmaceutical Group Co., Ltd.NCT07052838 Efficacy and Safety of HSK39297 in Anti-C5 Treated PNH Patients With AnemiaParoxysmal Nocturnal Haemoglobinuria (PNH)completed36
2025-12-24P1/P2Incyte Corporation INCYNCT02917993 An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung CancerLung Cancercompleted59
2025-12-24P1/P2Xencor, Inc. XNCRNCT06173505 Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLCNonsquamous Non-small Cell Lung Cancerterminated28
2025-12-24P3Novavax NVAXNCT06291857 A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination VaccineCOVID-19completed9320
2025-12-25P3Sanofi Pasteur, a Sanofi Company SNYNCT07222059 Phase 3 Single Arm, Open Study on vYF in AdultsYellow Fevercompleted254
2025-12-26P3Sanofi SNYNCT03485677 Safety and Efficacy of Eliglustat With or Without Imiglucerase in Pediatric Patients With Gaucher Disease (GD) Type 1 and Type 3Gaucher's Disease Type I; Gaucher's Disease Type IIIcompleted57
2025-12-26P2Hoffmann-La RocheNCT05661578 A Study to Evaluate the Safety and Pharmacokinetics of the Intravenous Fixed-Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants With LocaPD-L1-selected Solid Tumorscompleted64
2025-12-28 est.P1/P2LetolabNCT06384248 Phase II Clinical Study of LTC004 in Patients With Advanced SarcomaUnresectable or Metastatic Sarcomaunknown30
2025-12-28 est.P1/P2NEXBIOME THERAPEUTICSNCT06450990 Efficacy, Safety, and Dose-response of a Live Biotherapeutic Product in Women With Acute Vaginal InfectionBacterial Vaginosis; Vulvovaginal Candidiasisunknown165
2025-12-29P3Pulmocide LtdNCT05238116 Safety and Efficacy of PC945 (Opelconazole) in Combination With Other Antifungal Therapy for the Treatment of Refractory Invasive Pulmonary Aspergillosis (OPERARefractory IPAterminated85
2025-12-29P2Merck Sharp & Dohme LLC MRKNCT05877547 A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)Non-alcoholic Fatty Liver Disease; Fatty Liver, Nonalcoholic; NAFLD; Nonalcoholic Fatty Liver Diseascompleted381
2025-12-29 est.P2/P3Convalife (Shanghai) Co., Ltd.NCT06293716 CVL237 Tablets for APDS/PASLIPI3K and P110delta Hyperactivation Syndromeunknown35
2025-12-29P2Axoltis PharmaNCT06365216 ALS Phase II Study of NX210cAmyotrophic Lateral Sclerosiscompleted83
2025-12-29P3BayerNCT06422507 A Study to Learn More About How Well 8 Milligram Aflibercept Works and How Safe it is in Chinese Participants With Diabetic Macular EdemaDiabetic Macular Edemacompleted333
2025-12-29P3Alexion Pharmaceuticals, Inc.NCT06764160 Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Eculizumab in Chinese Adults With gMGGeneralized Myasthenia Gravis (gMG); Refractory gMGcompleted15
2025-12-29P2Pfizer PFENCT06897202 A Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight and T2DMObesity in Diabetes; Type 2 Diabetes Mellitus (T2DM)completed133
2025-12-29P1/P2Aurigene Discovery Technologies LimitedNCT07040059 A Phase 1b/2 Clinical Trial Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AUR103 Calcium in Patients With HER2-positive Advanced GaHER 2 Positive Gastric Cancer; Gastroesophageal Junction Adenocarcinomaterminated2
2025-12-30 est.P3Xcovery Holdings, Inc.NCT02767804 eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) PatientsNon-small Cell Lung Canceractive not recruiting290
2025-12-30 est.P3OBI Pharma, IncNCT03562637 Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBCTriple Negative Breast Canceractive not recruiting575
2025-12-30 est.P1/P2Ascentage Pharma Group Inc. AAPGNCT03611868 A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid TumorsUnresectable or Metastatic Melanoma or Advanced Solid Tumors; Melanoma; Uveal Melanoma; P53 Mutationactive not recruiting230
2025-12-30 est.P2Chase Therapeutics Corporation WHLTNCT03642964 A Study in Patients With Major Depressive DisorderMajor Depressive Disorder (MDD)unknown24
2025-12-30 est.P2Chase Therapeutics Corporation WHLTNCT03683225 A Study to Evaluate in Patients With Parkinsonian Type DisordersIdiopathic Parkinson Diseaseunknown24
2025-12-30P1/P2Genmab GMABNCT04083599 GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid TumorsMalignant Solid Tumor; Non-Small Cell Lung Cancer (NSCLC); Colorectal Cancer (CRC); Melanoma; Head aactive not recruiting350
2025-12-30P3Hoffmann-La RocheNCT04294810 A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally AdvNon-Small Cell Lung Cancercompleted620
2025-12-30 est.P1/P2Beijing InnoCare Pharma Tech Co., Ltd.NCT04304040 A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell LymphomaB-cell Lymphoma Recurrent; B-cell Lymphoma Refractoryunknown43
2025-12-30P1/P2Antengene CorporationNCT04425070 A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cePeripheral T-cell Lymphoma; NK/T-cell Lymphomaterminated56
2025-12-30 est.P3AkesoNCT04982237 A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical CancerCervical Canceractive not recruiting445
2025-12-30 est.P1/P2AkesoNCT04982276 A Study of AK109 and AK104 in Advanced Gastric Adenocarcinoma or Gastroesophageal Junction AdenocarcinomaGastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinomarecruiting138
2025-12-30P3Hoffmann-La RocheNCT05047250 A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung CancerNon-Small Cell Lung Canceractive not recruiting60
2025-12-30 est.P1/P2HELP Therapeutics Co., Ltd.NCT05223894 Treating Heart Failure With hiPSC-CMsHeart Failureunknown20
2025-12-30 est.P2Tarapeutics Science Inc.NCT05241093 A Study of HYML-122 and Cytarabine in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)Relapsed or Refractory Acute Myeloid Leukemia (AML)unknown18
2025-12-30 est.P2Tarapeutics Science Inc.NCT05241106 A Study of HYML-122 in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)Relapsed or Refractory Acute Myeloid Leukemia (AML)unknown15
2025-12-30 est.P3AkesoNCT05244642 A Phase III Study to Evaluate the Efficacy and Safety of Penpulimab in the Relapsed and Refractory Classical Hodgkin's LymphomaHodgkin Disease Lymphomaunknown60
2025-12-30P1/P2Tango Therapeutics, Inc. TNGXNCT05275478 Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid TumorsLocally Advanced Solid Tumorterminated110
2025-12-30 est.P2Kintara Therapeutics, Inc.NCT05374915 Efficacy and Safety Study of REM-001 Photodynamic Therapy for Treatment of Cutaneous Metastatic Breast Cancer (CMBC)Cutaneous Breast Canceractive not recruiting15
2025-12-30P2/P3Quoin Pharmaceuticals QNRXNCT05521438 Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton SyndromeNetherton Syndromeactive not recruiting30
2025-12-30P1/P2Grit BiotechnologyNCT05729399 Clinical Study of Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for Advanced Solid TumorsSolid Tumorterminated6
2025-12-30 est.P3Telix Pharmaceuticals (Innovations) Pty Limited TLXNCT05847348 68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese PatientsBiochemical Recurrence of Malignant Neoplasm of Prostate; Prostate Cancer; BCR Prostate Carcinomaunknown110
2025-12-30 est.P1/P2GI Cell, Inc.NCT05880043 GIC-102, Intravenous Allogeneic NK Cells, in Subjects With Advanced Solid Cancers and R/R Hematologic MalignanciesAdvanced Solid Tumors; Relapsed/Refractory Non-Hodgkin Lymphoma; Relapsed/Refractory Multiple Myelomunknown50
2025-12-30 est.P3Energenesis Biomedical Co., Ltd.NCT05930210 A Study to Evaluate ENERGI-F703 GEL in Diabetic Foot UlcerDiabetic Foot Ulcer; Foot Ulcer; Diabetes Mellitus; Woundrecruiting230
2025-12-30 est.P1/P2Genfleet Therapeutics (Shanghai) Inc.NCT05934513 A Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)unknown95
2025-12-30P3Mineralys Therapeutics Inc. MLYSNCT05968430 Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With HypertensionHypertensionactive not recruiting1076
2025-12-30 est.P2Abbisko Therapeutics Co, LtdNCT06111274 A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic CancerAdvanced Pancreatic Cancerrecruiting82
2025-12-30 est.P1/P2Indapta Therapeutics, INC.NCT06119685 IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic CancersNHL; Multiple Myeloma; Blood Cancer; Refractory Non-Hodgkin Lymphoma; Relapsed Non-Hodgkin Lymphoma;recruiting128
2025-12-30 est.P1/P2CNBG-Virogin Biotech (Shanghai) Ltd.NCT06124001 Clinical Study of VG161 Combined With Camrelizumab in Patients With Advanced Primary Hepatocellular CarcinomaPrimary Hepatocellular Carcinomaunknown36
2025-12-30P1/P2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT06245941 A Clinical Trial of TQ05105 Tablets Combined With TQB3909 Tablets in the Treatment of Myelofibrosis (MF)Myelofibrosisterminated21
2025-12-30 est.P2Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT06247956 Study of SHR-8068 Combined With Adebrelimab and Platinum-containing Chemotherapy in the Treatment of Advanced Gastric and Esophageal CancerAdvanced Gastric Adenocarcinoma and Esophageal Squamous Cell Carcinomaactive not recruiting153
2025-12-30 est.P2/P3Shanghai Huaota Biopharmaceutical Co., Ltd.NCT06477536 Long-Term Safety and Efficacy of HB0034 in Subjects With Generalized Pustular PsoriasisGeneralized Pustular Psoriasisunknown33
2025-12-30 est.P3Jiangxi Qingfeng Pharmaceutical Co. Ltd.NCT06573008 Study of GP681 Tablets Compared With Placebo in Patients With Influenza at High Risk of Influenza ComplicationsInfluenza, Humanrecruiting328
2025-12-30 est.P2/P3Resverlogix CorpNCT06590324 A Study of Apabetalone in Subjects With Long -COVIDPost-Acute COVID-19 Syndromerecruiting200
2025-12-30 est.P2Keymed Biosciences Co.LtdNCT06594146 Study of CM313 (SC) Injection in Subjects With Primary Immune Thrombocytopenia (ITP)Primary Immune Thrombocytopeniaactive not recruiting62
2025-12-30P1/P2Sinovac Biotech Co., Ltd SVANCT06754384 Tolerability, Safety, and Immunogenicity of Tetravalent Inactivated Enterovirus Vaccine (Vero Cell).Hand, Foot, and Mouth Disease (HFMD); Herpanginacompleted552
2025-12-30 est.P1/P2Zhejiang Yangli Pharmaceutical Technology Co., Ltd.NCT06819215 Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid TumorsCancer; Neoplasms; Neoplasms, Breast; Tumor; PARP; Ovarian Neoplasms; Prostatic Cancer; Pancreatic Crecruiting188
2025-12-30 est.P3Wuhan Createrna Science and Technology Co., LtdNCT06932471 Study of Safety and Efficacy of MY008211A in Patients With Residual Anemia Despite Anti-C5 Antibody TreatmentParoxysmal Nocturnal Hemoglobinuriarecruiting20
2025-12-30 est.P3Wuhan Createrna Science and Technology Co., LtdNCT06932744 Study of Safety and Efficacy of MY008211A in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor TherapyParoxysmal Nocturnal Haemoglobinuria (PNH)recruiting66
2025-12-30P3Sarfez Pharmaceuticals, Inc.NCT07015671 Bioavailability and Bioequivalence Study of ER Torsemide and Spironolactone FDC Tablet in Healthy SubjectsBioequivalence Study in Healthy Subjects; PK/PDcompleted24
2025-12-30P3Sarfez Pharmaceuticals, Inc.NCT07043634 A Study to Evaluate the Effect of Food or no Food on the Bioavailability of an Extended Release (ER) Torsemide and Spironolactone Fixed Dose Combination (FDC) TBioavailability Heathy Volunteerscompleted24
2025-12-30P3Colgate Palmolive CLNCT07210138 Clinical Investigation of PerioGard (Test) RegimenGingivitiscompleted80
2025-12-30P2Jiangsu HengRui Medicine Co., Ltd.NCT07252921 Safety and Efficacy of HRS-9190 Compared to Rocuronium for Tracheal Intubation in AdultsNeuromuscular Blockadecompleted70
2025-12-30 est.P2Haisco Pharmaceutical Group Co., Ltd.NCT07331402 A Clinical Study Evaluating the Pharmacokinetics and Pharmacodynamics of HSK39004 Inhalation Suspension in COPD PatientsCOPD Patientsactive not recruiting12
2025-12-31 est.P3United BioPharma UTHRNCT03149211 To Investigate the Efficacy and Safety of UB-421 Monotherapy in HIV-1 Infected AdultsHIV-1 Infectionwithdrawn
2025-12-31P3United Therapeutics UTHRNCT03626688 A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH PatientsPAH; Pulmonary Hypertension; Pulmonary Arterial Hypertension; Hypertension; Connective Tissue Diseascompleted687
2025-12-31P1/P2RemeGen Co., Ltd.NCT04175847 A Phase I /IIa Study of RC88-ADC in Subjects With Advanced Malignant Solid TumorsSolid Tumorcompleted198
2025-12-31 est.P2Vasgene Therapeutics, IncNCT04486781 A Study of Pembrolizumab+ sEphB4 in Metastatic Urothelial CarcinomaMetastatic Urothelial Carcinomaunknown38
2025-12-31 est.P3Philogen S.p.A.NCT04650984 A Study Comparing the Efficacy of L19TNF+Doxorubicin vs Doxorubicin Alone as First-line Therapy in Patients With Advanced or Metastatic Soft Tissue SarcomaSoft Tissue Sarcomaunknown102
2025-12-31 est.P2MitoImmune TherapeuticsNCT04651634 MIT-001 for Prevention of CCRT-Induced OM in HNSCC PatientsHead and Neck Squamous Cell Carcinoma; Oral Mucositisactive not recruiting60
2025-12-31 est.P2HUYABIO International, LLC.NCT04680026 A Study of IV HBI-3000 for the Conversion Recent Onset Atrial Fibrillation (AF)Atrial Fibrillationactive not recruiting150
2025-12-31 est.P1/P2Sardocor Corp.NCT04703842 Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection FractionCongestive Heart Failure; Heart Failure, Systolic; Heart Failure; HFrEF - Heart Failure With Reducedrecruiting57
2025-12-31P3Innovent Biologics (Suzhou) Co. Ltd.NCT04720716 A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCCHepatocellular Carcinomacompleted344
2025-12-31 est.P1/P2NanoRay Biotech Co., Ltd.NCT04807257 Auger Molecular Therapy (AMT) for Malignant Cutaneous Lesions TreatmentMalignant Fungating Woundrecruiting18
2025-12-31 est.P3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT04955834 A Clinical Study of Insulin Degludec Injection in Subjects With Type 2 DiabetesType 2 Diabetesunknown344
2025-12-31P1/P2ExCellThera inc.NCT04990323 US Study of ECT-001-CB in Pediatric and Young Adult Patients With High-Risk Myeloid MalignanciesHigh Risk Myeloid Malignancies; Cord Blood Transplantcompleted13
2025-12-31P3AstraZeneca AZNNCT05043090 Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCCPapillary Renal Cell Carcinomaactive not recruiting148
2025-12-31P3BayerNCT05047263 A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney DiseaseNon-diabetic Chronic Kidney Diseasecompleted1584
2025-12-31 est.P3KeifeRx, LLCNCT05143528 Evaluating the Efficacy and Safety of Nilotinib BE in Subjects With Early Alzheimer's DiseaseAlzheimer Diseaseunknown1275
2025-12-31 est.P1/P2Shanghai EpimAb Biotherapeutics Co., Ltd.NCT05176665 EMB-01 in Patients With Advanced/Metastatic Gastrointestinal CancersNeoplasms; Neoplasm Metastasis; Metastatic Gastrointestinal Carcinoid Tumorunknown152
2025-12-31P2AkesoNCT05256472 A Study of AK104 Monotherapy or AK104 Plus Axitinib in Advanced/Metastatic Renal Cell CarcinomaRenal Cell Carcinoma; First-line Treatmentcompleted28
2025-12-31 est.P2Innovent Biologics (Suzhou) Co. Ltd.NCT05280626 First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOPDiffuse Large B-Cell Lymphomanot yet recruiting100
2025-12-31 est.P2Jiangsu HengRui Medicine Co., Ltd.NCT05353361 A Phase Ib/II Study of SHR-A1811 Injection in Breast CancerBreast Cancerunknown402
2025-12-31 est.P2OBI Pharma, IncNCT05442060 To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small CNon-small Cell Lung Cancerrecruiting60
2025-12-31 est.P3EpicentRx, Inc.NCT05566041 A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung CancerCarcinoma, Small Cell Lungunknown292
2025-12-31P2RemeGen Co., Ltd.NCT05628857 A Study of RC108-ADC in Subjects With Advanced Digestive System Malignant TumorDigestive Cancercompleted29
2025-12-31 est.P1/P2Minghui Pharmaceutical Pty LtdNCT05642949 Study of MHB036C in Participants With Advanced or Metastatic Solid TumorsAdvanced Solid Tumorunknown400
2025-12-31 est.P1/P2HotSpot Therapeutics, IncNCT05662397 A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 AntibodySolid Tumor, Adult; Relapsed Cancer; Refractory Canceractive not recruiting77
2025-12-31P1/P2Sonnet BioTherapeuticsNCT05756907 Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian CancerAdvanced Solid Tumor; Platinum-resistant Ovarian Cancerterminated40
2025-12-31P1/P2GeneCradle IncNCT05793307 Evaluation of the Safety and Efficacy of Infantile-onset Pompe Disease Gene Therapy DrugPompe Disease Infantile-Onsetactive not recruiting16
2025-12-31 est.P2Hansoh BioMedical R&D CompanyNCT05830123 ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other SarcomasOsteosarcoma; Sarcomarecruiting170
2025-12-31 est.P2Orexa BVNCT05923086 Preventing Gastrointestinal Disturbance in Patients After Longitudinal Laparotomy.Ileus Postoperativeunknown126
2025-12-31P1/P2NervGen Pharma NGENNCT05965700 NVG-291 in Spinal Cord Injury SubjectsSpinal Cord Injuries; Chronic Spinal Cord Injury; Subacute Spinal Cord Injurycompleted24
2025-12-31 est.P3Beijing InnoCare Pharma Tech Co., Ltd.NCT06004856 Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Chronic Primary Immune ThrombocytopeniaChronic Primary Immune Thrombocytopenia (ITP)unknown195
2025-12-31 est.P1/P2Chongqing Precision Biotech Co., LtdNCT06006390 CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid TumorsGastric Cancer; Colon Cancer; Rectal Cancer; Esophageal Cancer; Pancreas Cancer; Lung Cancer; Breastunknown60
2025-12-31 est.P2Hansoh BioMedical R&D CompanyNCT06014190 HS-20089 in Patients With Ovarian Cancer and Endometrial CancerOvarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer; Endometrial Cancerrecruiting460
2025-12-31 est.P1/P2RemeGen Co., Ltd.NCT06016062 A Study of RC148 As a Single Agent and Combination Therapy in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid TumorsSolid Tumorrecruiting221
2025-12-31 est.P2Jiangsu Renocell Biotech CompanyNCT06058078 RY_SW01 Cell Injection Therapy in Active Lupus NephritisLupus Nephritisrecruiting60
2025-12-31 est.P1/P2Jiangsu Renocell Biotech CompanyNCT06058091 RY_SW01 Cell Injection Therapy in Systemic SclerosisSystemic Sclerosisrecruiting81
2025-12-31 est.P2CellSight Technologies, Inc.NCT06107374 Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAGAdvanced Non Small Cell Lung Cancerunknown20
2025-12-31P2RemeGen Co., Ltd.NCT06173037 RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal CancerPrimary Peritoneal Cancer; Fallopian Tube Cancer; Epithelial Ovarian Cancercompleted43
2025-12-31 est.P1/P2Jiangsu HengRui Medicine Co., Ltd.NCT06173999 A Study of SHR2554 With Chemotherapy in Treatment-naïve Patients With Peripheral T-cell LymphomaPeripheral T-cell Lymphomaunknown100
2025-12-31 est.P1/P2Guangzhou Jiayin Biotech LtdNCT06183814 A Study of EXG102-031 in Participants With wAMDNeovascular Age-related Macular Degenerationunknown42
2025-12-31 est.P2Dizal PharmaceuticalsNCT06276283 DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29)Non-small Cell Lung Cancerrecruiting60
2025-12-31 est.P1/P2MB PHARMA s.r.o.NCT06319235 Clinical Trial to Demonstrate the Safety and Efficacy of DUOFAG®Surgical Site Infection; Staphylococcus Aureus Infection; Pseudomonas Aeruginosa Infection; Bacteriaunknown52
2025-12-31P2Fulgent Pharma LLC.NCT06332092 FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell CarcinomaHead and Neck Squamous Cell Carcinomaactive not recruiting46
2025-12-31 est.P3Valenta Pharm JSCNCT06379542 Efficacy and Safety of XC8, Film-coated Tablets, in Children With Acute Respiratory Viral InfectionsAcute Respiratory Infectionunknown252
2025-12-31P3RDC Clinical Pty LtdNCT06440252 Effectiveness of a Grape Seed Extract on Circulatory Measures in Healthy AdultsCirculatory; Changecompleted35
2025-12-31 est.P2Shanghai Bao Pharmaceuticals Co., Ltd.NCT06607016 A Clinical Trial With KJ103 in Anti-GBM DiseaseAnti-Glomerular Basement Membrane Diseaseactive not recruiting12
2025-12-31 est.P2BeBetter Med IncNCT06706713 Study of BEBT-109 in Subjects With EGFR Exon 20 Insertion Mutations Non-Small Cell Lung CancerNon-Small Cell Lung Cancer; EGFR Exon 20 Insertion Mutationrecruiting200
2025-12-31P3Visirna Therapeutics HK LimitedNCT06712771 A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of VSA003 in Chinese HoFH PatientsHomozygous Familial Hypercholesterolemia (HoFH)active not recruiting46
2025-12-31 est.P2Shenzhen Salubris Pharmaceuticals Co., Ltd.NCT06737081 SAL-0951 in the Treatment of Chemotherapy-induced Anemia in Patients With Non-myeloid MalignanciesAnemiarecruiting60
2025-12-31 est.P3NPO PetrovaxNCT06834100 Assessment of Immunogenicity, Reactogenicity and Safety of the Drug GNG-DE in Comparison With the Reference DrugInfections; Meningococcalrecruiting240
2025-12-31 est.P2Shanghai JMT-Bio Inc.NCT06892431 JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal CancerRecurrent or Metastatic Nasopharyngeal Cancer; Patients Who Have Experienced Treatment Failure at Lenot yet recruiting150
2025-12-31 est.P2Jianmin Pharmaceutical Group Co., LTD.NCT06932328 Qinqiao Yan Shu Granules for the Treatment of Acute Pharyngitis (Exterior Wind-Heat Syndrome) Phase II Clinical TrialAcute Pharyngitisrecruiting216
2025-12-31P1/P2Ariceum Therapeutics GmbHNCT06939036 Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )Small Cell Lung Cancer Extensive Stage; Merkel Cell Carcinomaterminated2
2025-12-31 est.P3Avizor SANCT06985875 Clinical Trial for the Evaluation of Safety and Efficacy of Drop 0.4%Eye Drynessnot yet recruiting79
2025-12-31 est.P3BeBetter Med IncNCT06998108 Study of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Patients With HR+/HER2- Locally Advanced or Metastatic BreasHR+/HER2- Locally Advanced, Metastatic Breast Cancerrecruiting330
2025-12-31 est.P3Daewoong Pharmaceutical Co. LTD.NCT07013279 Evaluate the Efficacy and Safety of DWP712 With Moderate to Severe Glabellar LinesGlabellar Linesnot yet recruiting324
2025-12-31 est.P3Sinotau Pharmaceutical GroupNCT07115238 Analysis of 18F-XTR006 PET Imaging in Cognitively Normal Subjects, and Patients With MCI and ADAlzheimer Disease; Neurofibrillary Tanglerecruiting354
2025-12-31P2/P3Shandong Suncadia Medicine Co., Ltd.NCT07185594 A Phase Ⅱ/Ⅲ Study of HRS-2129 for Postsurgical Pain Management in Abdominal SurgeryPostoperative Analgesiacompleted156
2025-12-31 est.P2Luye Pharma Group Ltd.NCT07236476 Identify Effective Doses of LY01021 in Controlled Ovarian Hyperstimulation (COH) for Female Subjects Undergoing Assisted Reproductive Technology (ART)Assisted Reproductionactive not recruiting90

← 2025-11 | 2026-01 →

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.